IMPACT Therapeutics, Inc (SEHK: 7630)
Health Care · Biotechnology · CN
HK$9.12
+8.64% today · -78.2% 1Y
IMPACT Therapeutics, Inc (SEHK: 7630) operates in the Biotechnology industry within the Health Care sector. The company is valued at $328.17M and employs 88 people.
Over the last twelve months the share price has lost 78.2%, trading between 7.87 and 47.98.
Tweenvest scores IMPACT Therapeutics, Inc across four factors: quality 42/100, value 70/100. Its strongest factor is value.
7630 price history
Key figures
- Market cap
- $328.17M
- Revenue (TTM)
- $17.40M
- P/E
- -9.27
- EPS
- -1.44
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$47.98
- 52-week low
- HK$7.87
- Avg volume (3M)
- —
- Shares outstanding
- 282.46M
- Employees
- 88
- Next earnings
- —
About IMPACT Therapeutics, Inc
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
- ISIN
- CNE100007LG4
- Founded
- 2009
- Listed since
- May 13, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Laekna, Inc.SEHK: 2105 | $338.09M | HK$6.23 | -5.82% |
| BioNote, Inc.KOSE: A377740 | $336.90M | ₩4,450.00 | -0.89% |
| BioDlink International Company LimitedSEHK: 1875 | $333.92M | HK$3.39 | +1.50% |
| Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd.SZSE: 300313 | $330.80M | CN¥9.20 | -3.97% |
| GC Corp.KOSE: A005250 | $325.65M | ₩9,580.00 | -1.44% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $324.03M | $5.98 | -0.99% |
| Enanta Pharmaceuticals, Inc.NasdaqGS: ENTA | $320.09M | $10.99 | -1.87% |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $318.59M | $3.12 | -1.58% |